Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report

BACKGROUND: Patients with metastatic colorectal cancer (mCRC) beyond second line treatment have a poor prognosis. Fruquintinib, regorafenib, trifluridine/tipiracil (TAS-102), panitumumab and cetuximab combined with single-agent chemotherapy regimens are currently recommended as third-line therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Yuming, Luo, Deyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007946/
https://www.ncbi.nlm.nih.gov/pubmed/36915460
http://dx.doi.org/10.21037/jgo-23-39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007946/
https://www.ncbi.nlm.nih.gov/pubmed/36915460
http://dx.doi.org/10.21037/jgo-23-39

Ejemplares similares